Background-Beyond their role as innate immune effectors, natural killer (NK) cells are emerging as important regulators of angiogenesis and vascular remodeling. Pulmonary arterial hypertension (PAH) is characterized by severe pulmonary vascular remodeling and has long been associated with immune dysfunction. Despite this association, a role for NK cells in disease pathology has not yet been described. Methods and Results-Analysis of whole blood lymphocytes and isolated NK cells from PAH patients revealed an expansion of the functionally defective CD56 Ϫ /CD16 ϩ NK subset that was not observed in patients with chronic thromboembolic pulmonary hypertension. NK cells from PAH patients also displayed decreased levels of the activating receptor NKp46 and the killer immunoglobulin-like receptors 2DL1/S1 and 3DL1, reduced secretion of the cytokine macrophage inflammatory protein-1, and a significant impairment in cytolytic function associated with decreased killer immunoglobulin-like receptor 3DL1 expression. Genotyping patients (nϭ222) and controls (nϭ191) for killer immunoglobulin-like receptor gene polymorphisms did not explain these observations. Rather, we show that NK cells from PAH patients exhibit increased responsiveness to transforming growth factor-, which specifically downregulates disease-associated killer immunoglobulin-like receptors. NK cell number and cytotoxicity were similarly decreased in the monocrotaline rat and chronic hypoxia mouse models of PAH, accompanied by reduced production of interferon-␥ in NK cells from hypoxic mice. NK cells from PAH patients also produced elevated quantities of matrix metalloproteinase 9, consistent with a capacity to influence vascular remodeling. Conclusions-Our work is the first to identify an impairment of NK cells in PAH and suggests a novel and substantive role for innate immunity in the pathobiology of this disease. (Circulation. 2012;126:1099-1109.)Key Words: immunology Ⅲ pulmonary hypertension Ⅲ natural killer cells Ⅲ transforming growth factor- P ulmonary arterial hypertension (PAH) is characterized by a loss of pulmonary vasculature at the level of the precapillary arterioles. This pathological vascular remodeling is marked by excessive muscularization of the remaining pulmonary arteries and the formation of obstructive vascular lesions associated with the aberrant proliferation of endothelial cells, vascular smooth muscle cells, and fibroblasts. The resulting elevation of pulmonary arterial pressure leads to right ventricular hypertrophy and death from right heart failure. Recently, members of the transforming growth factor- (TGF-) superfamily have been recognized as critical mediators of pulmonary vascular remodeling. Mutations in the gene encoding the bone morphogenetic protein type II receptor account for Ͼ70% of heritable PAH cases and 15% to 40% of cases of the sporadic form of the disease. 1 Reduced bone morphogenetic protein signaling and heightened TGF- signaling have been reported in pulmonary vascular cells from PAH patients, whether or not...